Your browser is no longer supported. Please, upgrade your browser.
AUPH Aurinia Pharmaceuticals Inc. daily Stock Chart
Aurinia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.66 Insider Own- Shs Outstand52.81M Perf Week9.78%
Market Cap450.45M Forward P/E- EPS next Y-0.48 Insider Trans- Shs Float22.79M Perf Month131.79%
Income- PEG- EPS next Q-0.14 Inst Own- Short Float14.84% Perf Quarter203.56%
Sales0.17M P/S2603.78 EPS this Y60.60% Inst Trans- Short Ratio0.45 Perf Half Y302.36%
Book/sh0.89 P/B9.55 EPS next Y-84.60% ROA- Target Price10.30 Perf Year184.33%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.74 - 10.54 Perf YTD306.19%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-19.07% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low390.79% ATR0.90
Employees12 Current Ratio- Sales Q/Q-47.40% Oper. Margin- RSI (14)66.47 Volatility11.86% 13.18%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.31 Prev Close8.37
ShortableYes LT Debt/Eq- EarningsMar 17 AMC Payout- Avg Volume7.44M Price8.53
Recom1.40 SMA2036.06% SMA5097.35% SMA200161.77% Volume9,694,450 Change1.91%
Mar-22-17Reiterated FBR & Co. Outperform $9 → $11
Dec-30-16Reiterated H.C. Wainwright Buy $10 → $8
Aug-17-16Reiterated H.C. Wainwright Buy $7 → $10
Jun-30-16Initiated H.C. Wainwright Buy $7
May-08-15Initiated MLV & Co Buy $9
Mar-22-17 08:47AM  Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Mar-21-17 10:39AM  Traders Are Aggressively Fading the Open
09:30AM  Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability Accesswire
Mar-20-17 04:05PM  Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters Option to Purchase Additional Common Shares Business Wire +14.03%
11:25AM  Biotechs Remain the Best Place For Stock Picking
09:06AM  Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-17-17 12:11PM  Shark Bites: Market Keeps Giving Back Gains
Mar-16-17 04:20PM  Why Aurinia Pharmaceuticals Shares Are on a Wild Ride Lately at Motley Fool
04:01PM  Aurinia Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017) Business Wire
10:16AM  Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
Mar-15-17 01:56PM  Aurinia Pharmaceuticals Inc (AUPH) In A Common Shares Public Offering To Raise Over $150 Million at Insider Monkey
Mar-14-17 04:03PM  Aurinias stock plunges after big share offering at deep discount at MarketWatch -25.05%
11:09AM  Lantheus Holdings, Aurinia, Whiting, Oasis, and More: What is Going on With These Five Falling Stocks? at Insider Monkey
10:50AM  Here's Why Aurinia Pharmaceuticals Dropped 25.5% at the Opening at Motley Fool
09:01AM  Twitter Traders Yap, but Aurinia Raising $150 Million was a Well-Executed Deal
08:00AM  Aurinia Prices US$150.5 Million Public Offering of Common Shares Business Wire
Mar-13-17 05:14PM  Market Takes 'National Napping Day' Seriously +24.00%
05:03PM  Why Mobileye, Aurinia Pharmaceuticals, and Blackstone Group Jumped Today at Motley Fool
05:01PM  Aurinia Pharmaceuticals shares drop on secondary offering plan at MarketWatch
04:01PM  Aurinia Announces Public Offering of Common Shares Business Wire
Mar-10-17 03:39PM  Aurinia Offers Promising 2017 Forecast (AUPH) at Investopedia +9.25%
08:15AM  Aurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session
07:37AM  Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
Mar-09-17 04:42PM  Here's Why Aurinia Pharmaceuticals Rose as Much as 15.6% Today at Motley Fool +8.66%
09:22AM  Aurinia reports 4Q loss
08:30AM  Aurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights Business Wire
Mar-08-17 10:59AM  Answering The Important Aurinia Pharmaceuticals Inc (AUPH) Questions at Insider Monkey
09:30AM  Today's Research Reports on Trending Tickers: MeetMe and Aurinia Pharmaceuticals Accesswire
Mar-07-17 11:53AM  Here's Why Aurinia Pharmaceuticals Stock Is Soaring Today at Motley Fool +32.46%
10:38AM  Woe to Those Who Are Trapped When the Daily Pattern Is Broken
Mar-06-17 04:05PM  Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings Business Wire +11.43%
Mar-03-17 11:54AM  Market Action Is Boring but Necessary +6.18%
09:30AM  Biotech Industry Rally Grows as Trump Vows to Cut Regulations: Today's Reports on Aurinia Pharmaceuticals and Nektar Therapeutics Accesswire
Mar-02-17 01:15PM  Patient Death Fears Allayed For Aurinia Pharmaceuticals Inc (AUPH), Whats Next? at Insider Monkey +22.10%
01:12PM  Aurinia to Present at Cowen and Company 37th Annual Healthcare Conference Business Wire
12:20PM  Thursdays Top Biopharma Movers
11:39AM  Aurinia Pharma Spikes on Lupus Drug Safety at Investopedia
11:15AM  Shark Bites: Market Taking a Break, but Probably Not for Long
09:32AM  Biotech Premarket Movers: Aurinia, Puma, PTC, Juno
Mar-01-17 04:12PM  Aurinia's lupus drug shows no new safety concerns
04:05PM  Aurinia Pharma Kidney Drug Exits Study Update with Clean Safety Profile
04:05PM  Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study Business Wire
Feb-22-17 08:20AM  Aurinia Pharmaceuticals (AUPH) Shares March Higher, Can It Continue? -7.61%
Feb-14-17 07:00AM  Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin Business Wire
Feb-10-17 02:44PM  Aurinias New CEO, Richard Glickman, to Present at Leerink Partners 6th Annual Global Healthcare Conference Business Wire
Feb-06-17 05:15PM  Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer Business Wire
Feb-03-17 09:35AM  Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?
Jan-30-17 08:25AM  Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
08:15AM  Blog Coverage Aurinia Chooses Worldwide Clinical Trials as CRO for AURORA Phase-3 Study of Voclosporin Accesswire
Jan-27-17 08:13AM  Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix +5.57%
08:00AM  Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial Business Wire
Jan-26-17 04:05PM  Aurinia Pharmaceuticals to Participate in Upcoming Conferences Business Wire
Jan-09-17 03:03PM  3 Microcaps With Recent 13-D Activist Investors
Jan-05-17 08:42AM  Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
Jan-04-17 11:52AM  These Biotech Stocks Could Run in 2017
Dec-28-16 05:56PM  Aurinia Closes US$28 Million Financing Business Wire
Dec-22-16 06:00AM  Aurinia Announces US$25.0 Million Bought Deal Financing Business Wire -20.96%
Dec-19-16 04:05PM  Aurinia Announces Long-Term Manufacturing Collaboration Agreement with Lonza for Clinical and Commercial Supply of Voclosporin Business Wire
Dec-15-16 05:39AM  Is Attunity Ltd (ATTU) A Good Stock To Buy? at Insider Monkey
Dec-14-16 08:33PM  How Gastar Exploration Inc (GST) Stacks Up Against Its Peers at Insider Monkey
Dec-13-16 08:00AM  Aurinia Confirms Receipt of FDA End of Phase 2 Meeting Minutes Business Wire
Dec-12-16 04:05PM  Aurinia Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee Business Wire
Nov-21-16 09:27AM  Aurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney Week 2016 Business Wire
Nov-17-16 11:43AM  Aurinia Aligns with FDA on Lupus Drug (AUPH) at Investopedia -15.31%
Nov-16-16 11:35AM  Aurinia Pharmaceuticals Rises on Positive Mid-Stage Update
08:00AM  Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology Annual Meeting Business Wire
Nov-10-16 01:35PM  Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference Business Wire +16.60%
Nov-09-16 05:05PM  Aurinia Establishes At-The-Market Facility Business Wire
Nov-08-16 11:00AM  Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016
Nov-04-16 07:50PM  Aurinia reports 3Q loss +5.88%
06:55PM  Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights Business Wire
Nov-03-16 10:45AM  Aurinia Pharmaceuticals Jumps on Phase 3 Trial Plans -7.94%
Nov-02-16 04:42PM  Aurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting With FDA Business Wire -5.78%
12:05PM  Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount
Oct-24-16 05:15PM  Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings Business Wire
Oct-11-16 08:00AM  Aurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on October 18, 2016 Business Wire -5.89%
Oct-06-16 12:35PM  Heres Why Aurinia Pharmaceuticals, Georgetown Bancorp, and Three Other Stocks Are on the Move Today at Insider Monkey +25.93%
10:20AM  Aurinia Pharma Skyrockets on Positive Data From Lupus Study at 24/7 Wall St.
08:00AM  Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis Business Wire
Sep-30-16 11:40AM  Heres Why Aurinia Pharmaceuticals, Alphabet, and Three Other Stocks Are in Spotlight on Friday at Insider Monkey +14.02%
Sep-29-16 04:54PM  Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN) Business Wire +9.09%
Sep-22-16 08:00AM  Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016 Business Wire +7.18%
Sep-21-16 08:00AM  Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York Business Wire
Sep-08-16 09:21AM  5 Stocks Under $10 That Could Make You a Lot of Money
Sep-07-16 08:00AM  Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference Business Wire
Aug-18-16 09:30AM  The Zacks Analyst Blog Highlights: Vertex, Aurinia, AVEO and Amgen -7.38%
Aug-17-16 03:49PM  Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data +5.63%
Aug-16-16 11:08AM  Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data +27.62%
10:55AM  Tuesdays Top Health Care Movers at 24/7 Wall St.
Aug-15-16 11:35AM  Aurinia Pharmaceuticals (AUPH) Stock Tumbles on Lupus Drug Trial Deaths -55.75%
10:58AM  Why These Five Stocks Are in Spotlight on Monday at Insider Monkey
10:40AM  Why Aurinia Pharma Is Getting Slaughtered at 24/7 Wall St.
06:00AM  Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis Business Wire
Aug-05-16 09:31AM  Aurinia reports 2Q loss
09:00AM  Aurinia Reports Second Quarter 2016 Financial Results and Operational Highlights Business Wire
Jul-28-16 07:56PM  Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York Business Wire
Jul-22-16 05:18PM  Aurinia Establishes At-The-Market Facility Business Wire
Jul-11-16 10:50AM  Aurinia Announces Appointment of Head of Communications & Advocacy Business Wire
Jun-30-16 07:16AM  Coverage initiated on Aurinia Pharma by H.C. Wainwright
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.